Evolus’ (NASDAQ:EOLS) quiet period is set to end on Tuesday, March 20th. Evolus had issued 5,000,000 shares in its public offering on February 8th. The total size of the offering was $60,000,000 based on an initial share price of $12.00. During Evolus’ quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
A number of research firms have weighed in on EOLS. Mizuho began coverage on shares of Evolus in a report on Monday, March 5th. They issued a “buy” rating and a $21.00 price objective for the company. Cantor Fitzgerald began coverage on shares of Evolus in a report on Monday, March 5th. They issued an “overweight” rating and a $25.00 price objective for the company. JMP Securities began coverage on shares of Evolus in a report on Monday, March 5th. They issued an “outperform” rating and a $20.00 price objective for the company. Finally, SunTrust Banks began coverage on shares of Evolus in a report on Monday, March 5th. They issued a “buy” rating and a $24.00 price objective for the company.
Shares of Evolus (NASDAQ EOLS) opened at $12.37 on Tuesday. The company has a market cap of $291.84 and a PE ratio of -22.91. Evolus has a one year low of $9.60 and a one year high of $12.97.
WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/03/13/evolus-incs-eols-quiet-period-to-end-on-march-20th.html.
Evolus, Inc is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.